Systematic review: Steroid withdrawal in anti-TNF-treated patients with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 3, 2010, Pages 313-323

  Bultman, E ^a   Kuipers, E J ^a   Van Der Woude, C J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; COLON; CROHN DISEASE; DISEASE DURATION; DRUG WITHDRAWAL; ENTERITIS; FOLLOW UP; HUMAN; ILEUM; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; PEDIATRICS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; STEROIDS; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 77954319060     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04373.x     Document Type: Review

References (74)

1. Travis SP, Stange EF, Lémann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006 55 (Suppl 1 i16 35.
2. Travis SPL, Stange EF, Lémann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008 2:24 62.
3. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004 99:1371 1385.
4. Lichtenstein GR, Hanauer SB, Sandborn WJ, et al. Management of Crohn's disease in adults. Am J Gastroenterol 2009 104:465 483.
5. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003 3:CD000543.
6. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006 55:47 53.
7. Feagan BG. 5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion. Clin Gastroenterol Hepatol 2004:2 376 378.
8. Tung J, Loftus EV Jr., Freese DK, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2006 12:1093 1100.
9. Faubion WA Jr., Loftus EV Jr., Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001 121:255 260.
10. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995 37:674 678.
11. Holtmann MH, Krummenauer F, Claas C, et al. Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci 2006 51:1516 1524.
12. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Int Med 1989 110:353 356.
13. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995 332:292 297.
14. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000 342:1627 1632.
15. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997 337:1029 1035.
16. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006 130:323 333.
17. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007 132:52 65.
18. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Eng J Med 2005 353:2462 2476. (Pubitemid 41770166)
19. Toruner M, Loftus EV Jr., Harmsen WS. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008 134:929 936.
20. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009 58:501 508.
21. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006 4:621 630.
22. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocortiocoid resistance and dependency in Crohn's disease. Gut 1994 35:360 362.
23. Garcia-Vidal C, Rodríguez-Fernández S, Teijón S, et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009 28:331 337.
24. Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology 2008 135:1442 1447.
25. Cohen RD. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis 2001 7 (Suppl 1 S17 22.
26. Hyams JS. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr Gastroenterol Nutr 2001 33 (Suppl 1 S36 9.
27. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000 95:3189 3194.
28. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004 126:402 413. (Pubitemid 38182297)
29. Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol 2006 40:55 63.
30. Ardizzone S, Colombo E, Maconi G, et al. Infliximab in treatment of Crohn's disease: the Milan experience. Dig Liver Dis 2002 34:411 418.
31. Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of Infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther 2001 15:1639 1646.
32. Bermejo F, López-Sanroman A, Hinojosa J, Castro L, Jurado C, Gómez-Beldal AB. Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis. Rev Esp Enferm Dig 2004 96:94 101.
33. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000 95:3469 3477.
34. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995 109:129 135.
35. Ferkolj I, Ihan A, Markovic S. CD19+ in intestinal mucosa predict the response to infliximab in Crohn's disease. Hepatogastroenterology 2005 52:1128 1133.
36. Gheorghe L, Gheorghe C, Badea M, et al. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania. Rom J Gastroenterol 2003 12:7 13.
37. Hommes DW, van de Heisteeg BH, van der Spek M, Bartelsman JF, van Deventer SJ. Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital. Inflamm Bowel Dis 2002 8:81 6.
38. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000 137:192 196.
39. Kinney T, Rawlins M, Kozarek R, France R, Patterson D. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol 2003 98:608 612.
40. Laharie D, Salzmann M, Boubekeur H, et al. Predictors of response to infliximab in luminal Crohn's disease. Gastroenterol Clin Biol 2005 29:145 149.
41. Lamireau T, Cézard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2004 10:745 750.
42. Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol 2006 4:1124 1129.
43. Menachem Y, Avidan B, Lavy A, et al. Increasing the infliximab dose is beneficial in Crohn's disease patients who responded to a lower dose and relapsed. Digestion 2005 72:124 128.
44. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003 52:998 1002.
45. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001 96:722 729.
46. Sample C, Bailey RJ, Todoruk D, et al. Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta. Can J Gastroenterol 2002 16:165 170.
47. Seiderer J, Göke B, Ochsenkühn T. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital. Digestion 2004 70:3 9.
48. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN Jr., Mannick EE. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001 35:823 828.
49. Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003 98:104 111.
50. Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002 97:2577 2587.
51. Wenzl HH, Reinisch W, Jahnel J, et al. Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up. Eur J Gastroenterol Hepatol 2004 16:767 773.
52. Witthöft T, Ludwig D. Effectiveness and tolerability of repeated treatment with infliximab in patients with Crohn's disease: a retrospective data analysis in Germany. Int J Colorectal Dis 2005 20:18 23.
53. Jewell DP, Satsangi J, Lobo A, et al. Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005 17:1047 1052.
54. Poupardin C, Lémann M, Gendre JP, et al. Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up. Gastroenterol Clin Biol 2006 30:247 252.
55. Sánchez JM, Maldonado JC, Torres EA, Rivera C. Infliximab in Hispanics: characterization of response to infliximab in an ethnic minority with Crohn's disease. P R Health Sci J 2005 24:11 7.
56. Magro F, Bastos R, Marques M, Costa Santos C. Infliximab dose intensification by shortening infusion intervals. Inflamm Bowel Dis 2008 14:432 434.
57. Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease. J Pediatr Gastroenterol Nutr 2003 36:632 636.
58. Din S, Cochrane CJ, Noble CL, Satsangi J, Arnott ID. Combination therapy of infliximab and azathioprine reduces disease progression in Crohn's disease. Inflamm Bowel Dis 2008 14:143 145.
59. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000 95:3490 3497.
60. Kugathasan S. Prolonged duration of response to infliximab in early pediatric Crohn's disease. J Pediatr Gastroenterol Nutr 2001 33 (Suppl 1 S40 3.
61. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002 359:1541 1549.
62. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007 132:863 873.
63. Lémann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006 130:1054 1061.
64. Cucchiara S, Romeo E, Viola F, et al. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. Dig Liver Dis 2008 40 (Suppl 2 S260 4.
65. Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005 100:75 9.
66. Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther 2007 25:675 680.
67. Sandborn WJ, Hanauer S, Loftus EV Jr., et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004 99:1984 1989.
68. Seiderer J, Brand S, Dambacher J, et al. Adalimumab in patients with Crohn's disease - safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther 2007 25:787 796.
69. Wyneski MJ, Green A, Kay M, Wyllie R, Mahajan L. Safety and efficacy of adalimumab in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr 2008 47:19 25.
70. Noe JD, Pfefferkorn M. Short-term response to adalimumab in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008 14:1683 1687.
71. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007 56:1232 1239. (Pubitemid 47300424)
72. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009 4:CD000545.
73. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008 371:660 667.
74. Sandborn WJ. One year data from the SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. DDW 2009 [Abstract #751f ].